| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Daniel J Rader | |
| Emil M Degoma | |||
| P2860 | cites work | A novel endothelial-derived lipase that modulates HDL metabolism | Q22009153 |
| Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages | Q24320180 | ||
| HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway | Q24323992 | ||
| Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter | Q24550969 | ||
| Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta | Q24598068 | ||
| Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice | Q24600864 | ||
| Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial | Q24648125 | ||
| Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice | Q24681140 | ||
| Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis | Q24812868 | ||
| Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial | Q28181984 | ||
| Molecular identification of high and low affinity receptors for nicotinic acid | Q28202556 | ||
| PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect | Q28206812 | ||
| Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study | Q28216693 | ||
| Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial | Q28236480 | ||
| Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib | Q28259638 | ||
| Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans | Q43290558 | ||
| High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization | Q43653251 | ||
| Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha | Q28273937 | ||
| Nicotinic acid receptor agonists differentially activate downstream effectors | Q28298974 | ||
| Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients | Q28308033 | ||
| Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype | Q28511354 | ||
| Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE | Q28513193 | ||
| Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting | Q28584943 | ||
| Oxpholipin 11D: an anti-inflammatory peptide that binds cholesterol and oxidized phospholipids | Q28752575 | ||
| Effects of torcetrapib in patients at high risk for coronary events | Q29619609 | ||
| Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor | Q30881181 | ||
| Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study | Q33577884 | ||
| Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, [...] | Q33643426 | ||
| A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 | ||
| Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages | Q33929735 | ||
| Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study | Q33942742 | ||
| Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis | Q33959456 | ||
| Influence of nicotinic acid on serum cholesterol in man. | Q33972172 | ||
| Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice | Q33982567 | ||
| Seeing red: flushing out instigators of niacin-associated skin toxicity. | Q34028776 | ||
| Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. | Q34144449 | ||
| Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins | Q34170352 | ||
| Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin | Q34190482 | ||
| Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit | Q34248584 | ||
| A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice | Q34559952 | ||
| Optimal medical therapy with or without PCI for stable coronary disease | Q34612445 | ||
| Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo | Q34828796 | ||
| Endothelial lipase is a major determinant of HDL level | Q34829121 | ||
| Endothelial lipase: a new lipase on the block | Q34981113 | ||
| Molecular regulation of HDL metabolism and function: implications for novel therapies | Q35191066 | ||
| The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. | Q35732501 | ||
| Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent | Q35793779 | ||
| Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches | Q35860029 | ||
| Antiinflammatory properties of HDL. | Q35919164 | ||
| Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients | Q36662681 | ||
| Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide | Q43664811 | ||
| Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease | Q43834212 | ||
| Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol | Q43862770 | ||
| Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. | Q43997276 | ||
| Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial | Q44063968 | ||
| Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo | Q44090023 | ||
| Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial | Q44783935 | ||
| High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits | Q44982506 | ||
| Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta | Q45146790 | ||
| Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. | Q45940733 | ||
| Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. | Q46090651 | ||
| Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice | Q46153586 | ||
| Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors | Q46212716 | ||
| Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc | Q46231225 | ||
| Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. | Q46333846 | ||
| Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia | Q46447595 | ||
| D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice | Q46450296 | ||
| Compromised LCAT function is associated with increased atherosclerosis | Q46630196 | ||
| Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resona | Q46701074 | ||
| Endothelial lipase is increased in vivo by inflammation in humans | Q46796575 | ||
| Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model. | Q46802379 | ||
| Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies | Q46858990 | ||
| Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population | Q46911886 | ||
| Illuminating HDL--is it still a viable therapeutic target? | Q46913574 | ||
| ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis | Q47748338 | ||
| Structural characterisation of the mouse nuclear oxysterol receptor genes LXRalpha and LXRbeta | Q47884555 | ||
| High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. | Q51473820 | ||
| Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. | Q51596506 | ||
| Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. | Q51620237 | ||
| Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. | Q53569234 | ||
| Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans | Q59275772 | ||
| Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice | Q64381105 | ||
| Production and characterization of a reconstituted high density lipoprotein for therapeutic applications | Q71766897 | ||
| Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) | Q72220309 | ||
| Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins | Q72410988 | ||
| Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits | Q72711480 | ||
| Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity | Q73440398 | ||
| Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study | Q73783104 | ||
| Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport | Q73832914 | ||
| Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits | Q74230827 | ||
| Causes of interscan variability of coronary artery calcium measurements at electron-beam CT | Q74290724 | ||
| Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis | Q74290884 | ||
| Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice | Q77739504 | ||
| Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux | Q80576677 | ||
| Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport | Q80819953 | ||
| Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits | Q81553526 | ||
| Apolipoprotein A-I mimetic peptides | Q82957586 | ||
| An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study | Q83309967 | ||
| A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome | Q84384910 | ||
| Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone | Q36736504 | ||
| Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides | Q36850018 | ||
| Liver X receptor and farnesoid X receptor as therapeutic targets | Q37019321 | ||
| Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A Metabolism | Q37038074 | ||
| High Density Lipoprotein Metabolism in Man | Q37047273 | ||
| Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans | Q37143381 | ||
| Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo | Q37151837 | ||
| Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk | Q37193386 | ||
| Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis | Q37253754 | ||
| Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? | Q37301808 | ||
| The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations | Q37323099 | ||
| Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis | Q37356255 | ||
| Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins | Q37386911 | ||
| Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo | Q37485026 | ||
| The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors | Q37628885 | ||
| Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis | Q38356091 | ||
| Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux | Q38377760 | ||
| Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial | Q38398332 | ||
| D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1. | Q39731327 | ||
| Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo | Q39746656 | ||
| An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI. | Q39784725 | ||
| Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits | Q40166036 | ||
| Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo | Q40422178 | ||
| Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study | Q40486175 | ||
| The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c | Q40524290 | ||
| Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. | Q40658862 | ||
| Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles | Q40720835 | ||
| A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits | Q40866383 | ||
| Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice | Q41697403 | ||
| Serial quantitative coronary angiography and coronary events | Q41737961 | ||
| L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation | Q41817158 | ||
| Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. | Q41829964 | ||
| Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano | Q41855576 | ||
| Intestinal ABCA1 directly contributes to HDL biogenesis in vivo | Q41896773 | ||
| Biochemical characterization of cholesteryl ester transfer protein inhibitors | Q42107210 | ||
| Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport | Q42126715 | ||
| Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesn't quite follow the script | Q42540496 | ||
| Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib | Q42562376 | ||
| Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans | Q42752695 | ||
| Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology? | Q42788509 | ||
| Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease | Q42807626 | ||
| Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis | Q42950549 | ||
| RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo | Q43049803 | ||
| Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. | Q43064370 | ||
| The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura | Q43095846 | ||
| Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial | Q43246793 | ||
| High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol | Q43287987 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 266-277 | |
| P577 | publication date | 2011-01-18 | |
| P1433 | published in | Nature Reviews Cardiology | Q2108444 |
| P1476 | title | Novel HDL-directed pharmacotherapeutic strategies | |
| P478 | volume | 8 |
| Q37416464 | A common functional promoter variant links CNR1 gene expression to HDL cholesterol level |
| Q36709656 | A novel approach to oral apoA-I mimetic therapy |
| Q37056843 | APO A2 -265T/C Polymorphism Is Associated with Increased Inflammatory Responses in Patients with Type 2 Diabetes Mellitus. |
| Q34950045 | Anticipatory role of high density lipoprotein and endothelial dysfunction: an overview |
| Q38732861 | ApoE controls the interface linking lipids and inflammation in atherosclerosis |
| Q92372987 | Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer |
| Q37957869 | Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis |
| Q34221770 | Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts |
| Q37688597 | Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection |
| Q36293610 | Approach to the patient with extremely low HDL-cholesterol |
| Q35800550 | Association of a Human FABP1 Gene Promoter Region Polymorphism with Altered Serum Triglyceride Levels |
| Q35879603 | Atherosclerosis |
| Q64079430 | Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly |
| Q58804822 | Creatine kinase, energy reserve, and hypertension: from bench to bedside |
| Q35917056 | Crosstalk between reverse cholesterol transport and innate immunity |
| Q37702199 | Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. |
| Q34718513 | Decrease in irisin in patients with chronic kidney disease |
| Q38706633 | Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits |
| Q38848673 | Detection and treatment of atherosclerosis using nanoparticles |
| Q39427274 | Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview |
| Q38127103 | Dietary approaches to improving atheroprotective HDL functions |
| Q63560435 | Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates |
| Q39771997 | Endothelial lipase inhibitors for the treatment of atherosclerosis and cardiovascular disorders |
| Q41771811 | Expressed protein ligation-mediated template protein extension |
| Q34429737 | Functional characterization of newly-discovered mutations in human SR-BI |
| Q37667665 | Functional genomics of the human high-density lipoprotein receptor scavenger receptor BI: an old dog with new tricks |
| Q24603711 | Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis |
| Q36344509 | Gene Therapy Targeting LDL Cholesterol but not HDL Cholesterol Induces Regression of Advanced Atherosclerosis in a Mouse Model of Familial Hypercholesterolemia |
| Q30275688 | Genetic variants in CETP increase risk of intracerebral hemorrhage |
| Q38240748 | HDL and cardiovascular disease |
| Q36918309 | HDL, Atherosclerosis, and Emerging Therapies |
| Q46866176 | HDL--is it too big to fail? |
| Q38087383 | HDL-C: clinical equipoise and vascular endothelial function |
| Q36150462 | High Density Lipoprotein and it's Dysfunction |
| Q91975923 | High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential |
| Q26775420 | High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk |
| Q37996363 | High-density lipoprotein and atherosclerosis: the role of antioxidant activity |
| Q43498643 | High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong? |
| Q38506490 | High-density lipoprotein-based drug discovery for treatment of atherosclerosis |
| Q36903963 | Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits |
| Q38066291 | Hypercholesterolemia links hematopoiesis with atherosclerosis. |
| Q37298694 | Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. |
| Q49757235 | Improved survival rate after myocardial infarction using an inducible cholesterol efflux (iCE) peptide: FAMP. |
| Q50621714 | Increased Hepatic Expression of Endothelial Lipase Inhibits Cholesterol Diet-Induced Hypercholesterolemia and Atherosclerosis in Transgenic Rabbits. |
| Q35811972 | Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport |
| Q36141666 | Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial |
| Q35606800 | Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. |
| Q37556042 | Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio. |
| Q38857349 | Metabolic regulation of magnolol on the nuclear receptor, liver X receptor |
| Q37650114 | Micro-RNAs and High-Density Lipoprotein Metabolism. |
| Q60675346 | MicroRNAs regulating lipid metabolism in atherogenesis |
| Q38125279 | Molecular biology of atherosclerosis |
| Q36037988 | Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease |
| Q37671683 | Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis |
| Q37123887 | Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex |
| Q27002774 | Niacin, an old drug with a new twist |
| Q26823249 | Novel therapies focused on the high-density lipoprotein particle |
| Q30455490 | Perspectives and opportunities for nanomedicine in the management of atherosclerosis. |
| Q37695401 | Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. |
| Q52647946 | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. |
| Q55173600 | Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients. |
| Q33972551 | Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey |
| Q21132391 | RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist |
| Q38003957 | Rationale for cholesteryl ester transfer protein inhibition |
| Q36443768 | Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians |
| Q35626943 | Regulation of ABCA1 functions by signaling pathways |
| Q31064738 | Substituted benzamides containing azaspiro rings as upregulators of apolipoprotein A-I transcription. |
| Q35974993 | Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein |
| Q42096573 | The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism |
| Q28388695 | The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects |
| Q38896299 | The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications |
| Q48175299 | The role of monocytosis and neutrophilia in atherosclerosis |
| Q36808201 | Vascular disease and dementias: paradigm shifts to drive research in new directions |
| Q83276925 | [HDL level or HDL function as the primary target in preventive cardiology] |
| Q37709886 | microRNAs in lipoprotein metabolism and cardiometabolic disorders. |
Search more.